Dermatology

Leo
Biotech

Leo's $435M deal for Tanabe skin disease drug awaiting FDA nod

Leo is sticking to its mission of strengthening its pipeline in 2026, securing a rare skin disease drug awaiting an approval decision by the FDA.
Marissa Russo Aug 18, 2026 3:00am
Goal disorientation and lack of vision

Celldex ends skin disease program after failing phase 2 test

Jul 22, 2026 6:00am
Completing steps towards success checkmark on cubes symbolizing progress

Racing Takeda, InnoCare reports TYK2 inhibitor win in vitiligo

Jul 16, 2026 9:36am
Goal disorientation and lack of vision

Evommune’s phase 2b flops, ending challenge to Novartis in hives

Jun 29, 2026 10:00am
skin cells epidermis layers lotion serum

Leo pays $50M for Replay and its skin disease gene therapy

Apr 30, 2026 9:00am
dynamic arrows moving up

Priovant will move brepocitinib to phase 3 after midstage win

Feb 6, 2026 7:00am